- ALK-positiv oder
- ROS1-positiv (2)
- Neutropenie
- verminderter Appetit
- Neuropathie
- Schwindel
- Dysgeusie
- Sehstörungen
- Erbrechen, Übelkeit
- Diarrhoe, Obstipathion
- Leukopenie
- Lymphopenie
- Anämie
- Hypophosphatämie
- Bradykardie
- Pneumonitis
- Ösophagusstörung
- Dyspepsie
- Exanthem
| Phase | Studie | NCT-Nummer | Bemerkungen |
| Phase III | Profil 1007 | 01154140 | fortgeschrittenes ALK - positives NSCLC, Randomized trial comparing docetaxel or PFS pemetrexed versus crizotinib as second-line treatment of advanced/metastatic ALK-rearranged NSCLC |
| Profil 1014 | 00932893 | First Line, fortgeschrittenes ALK - positives NSCLC, Critozinib versus Carboplatin - Pemetrexed, Randomized trial comparing platinum/pemetrexed PFS versus crizotinib in treatment-nai've advanced/ metastatic ALK-rearranged NSCLC | |
| Phase II | PROFILE 1005 | 00932451 | Clinical efficacy and safety of crizotinib in RR patients with ALÄT-rearranged NSCLC who were previously treated for their advanced NSCLC |
| PROFILE 1013 | 01121588 | Clinical efficacy and safety of crizotinib in ALK- RR rearranged tumors except NSCLC | |
| CREATE (EORTC 91010) | 01524926 | Cross tumoral study exploring crizotinib in RR patients with advanced tumors induced by causal alterations of ALK and/or cMET | |
| SWOG 1300 | Second Line, Pemetrexed +- Critozinib | ||
| Phase I | PROFILE 1001 | 00858195 | Original Crizotinib Phase I Trial, ALK-negatives NSCLC (cMET amplified) und ROS-rearranged Tumore |
| A8081002 | 00965731 | Kombination von Crizotinib und Erlotinib | |
| A8081006 | 01121575 | Kombination von Crizotinib und Dacomitinib | |
| COG-ADVL0912 | 00939770 | Children's Oncology Group Phase I Studie, rezidivierte und refraktäre solide Tumoren, ALCL |
Ceritinib in ALK-rearranged non-small-cell lung cancer.
NEJM 370(2014):1189-1197
2.) Shaw AT, et al.:
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
N Engl J Med 2014;371:1963–1971.
